Personalized antiplatelet therapy: Review of the latest clinical evidence

Current Cardiology Reports

Volumn 13, Issue 4, 2011, Pages 296-302

  Camilleri, Elise ^a   Jacquin, Laurent ^b   Paganelli, Franck ^c   Bonello, Laurent ^c  

^a Hopital de Martigues   (France)

^b TIMONE HOSPITAL   (France)

^c HÔPITAL NORD   (France)

Author keywords

Acute coronary syndrome; Antiplatelet; Clopidogrel; CYP450; Cytochrome P450; Genes; Genetics; High on treatment platelet reactivity; P2Y12 ADP receptor antagonist; Percutaneous coronary intervention; Platelet reactivity; Polymorphism; Prasugrel; Stent thrombosis; Therapy; Ticagrelor; Vasodilator stimulated phosphoprotein; VerifyNow P2Y12 device

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; ELINOGREL; P2Y12 ADP RECEPTOR ANTAGONIST; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG;

BLEEDING; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; REVIEW; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; STENTS; TICLOPIDINE;

EID: 80052486892     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0194-1     Document Type: Review

References (47)

1. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-7. (Pubitemid 32144286)
2. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation. 1991;83:148-61.
3. Investigators CURE. Clopidogrel in unstable angina to prevent recurrent events trial effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-33.
4. Järemo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002;252:233-8.
5. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated-phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003;59:295-302. (Pubitemid 36792384)
6. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-5.
7. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost. 2007;98:1329-34. (Pubitemid 350239106)
8. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29:992-1000. (Pubitemid 351844676)
9. Gurbel PA, Bliden KP, Samara W, et al. The clopidogrel resistance and stent thrombosis (CREST) study. J Am Coll Cardiol. 2005;46:1827-32.
10. Buonamici P, Marcucci R, Miglironi A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49:2312-7. (Pubitemid 46891710)
11. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilatorstimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5:1630-6. (Pubitemid 47091403)
12. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of care assay: a 12- month follow- up. Circulation. 2009;119:237-342.
13. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 2006;3:387-95. (Pubitemid 43978399)
14. Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos. 2009;37:2145-52.
15. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-9.
16. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288-95. (Pubitemid 35265838)
17. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA. 2006;103:11069-74. (Pubitemid 44148419)
18. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-62.
19. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 lossof- function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916-22.
20. Mega J, Simon T, Anderson JL, et al. CYP2C19 genetic variants and clinical outcomes with clopidogrel: a collaborative metaanalysis. Circulation. 2009;120(Suppl):s598.
21. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP. J Am Coll Cardiol 2010. In press. In this consensus paper, the authors summarize the evidence of a link between platelet reactivity inhibition and the occurrence of thrombotic events post-PCI. They also aim to define HTPR to be used in future trials to help standardize the literature.
22. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15. (Pubitemid 350106708)
23. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.
24. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost. 2010;8:250-6.
25. Mokhtar OA, Lemesle G, Armero S. et al Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res. 2010;126:147-9.
26. Cuisset T, Cayla G, Frere C, et al. Predictive value of posttreatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Euro- Intervention. 2009;5:325-9.
27. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-62.
28. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-75.
29. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309-17.
30. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-7. (Pubitemid 44497506)
31. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 lossof- function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916-22.
32. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19* 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-8. In this paper, Sibbing et al. suggest that PR inhibition predicts not only thrombotic events, but also bleeding events.
33. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-57.
34. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404-11. (Pubitemid 351447314)
35. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol. 2009;103:5-10 This study is the first to suggest that PR monitoring may improve the prognosis of patients undergoing PCI, promoting individualized antiplatelet regimen
36. Aleil B, Jacquemin L, DePoli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator- Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Intv. 2008;1:631-8.
37. Campo G, Valgimigli M, Gemmati D, et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol. 2007;50:1132-7. (Pubitemid 47375009)
38. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance) randomized study. J Am Coll Cardiol. 2009;53:1101-9.
39. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation. 2009;119:3215-22.
40. 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol. 2010;56:1447-55.
41. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-32.
42. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.
43. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119:2553-60.
44. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188-99.
45. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.
46. Bonello-Palot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009;104:1511-5.
47. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097-105.